| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5596844 | The Annals of Thoracic Surgery | 2017 | 8 Pages |
Abstract
Preoperative use of ARBs, but not ACEis, confers a benefit within 30 days after cardiac operations in patients with metabolic syndrome, suggesting potential efficacy differences of these drug classes in reducing cardiovascular morbidity and death in ambulatory vs surgical patients.
Keywords
ANGIIstandardized mean differencesAngiotensin receptor type 2AT2SMDLVEFPCIAT1TIAARBCVAAKIHDLCPBeuroSCOREhigh-density lipoproteinacute kidney injuryMyocardial infarctionAngiotensin IIcardiopulmonary bypassleft ventricleChronic obstructive pulmonary diseaseCOPDCABGGEEtransient ischemic attackRASIMetabolic syndromeCerebrovascular accidentbody mass indexBMIadverse eventconfidence intervalMETSpercutaneous coronary interventionAngiotensin receptor blockergeneralized estimating equationACEI یا angiotensin convert enzyme inhibitorangiotensin-converting enzyme inhibitorodds ratioAngiotensin receptor type 1POAFCoronary artery bypass graftleft ventricular ejection fraction
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Michael W. MD, PhD, Mary MS, Joseph MD, MHSc, John MD, MPH, Eric MD, T. Bruce MD, Renato MD, PhD, Mihai MD,